The US Food and Drug Administration (FDA) has accepted MSD’s doravirine/islatravir (DOR/ISL) new drug application (NDA) for review to treat adults with virologically suppressed human immunodeficiency ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback